Publications in collaboration with researchers from Universidad Miguel Hernández de Elche (81)

2024

  1. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

    Pharmaceutics, Vol. 16, Núm. 3

  2. Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Intestinal parasitic infections and their potential risk factors among prison inmates in Valencia, Spain

    BMC Infectious Diseases, Vol. 23, Núm. 1

2022

  1. Anemia and undernutrition in intestinally parasitized schoolchildren from Gakenke district, Northern Province of Rwanda

    PLoS ONE, Vol. 17, Núm. 1 January

  2. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen

    International Journal of Pharmaceutics, Vol. 614

2021

  1. Evidence for Transmission of Taenia solium Taeniasis/Cysticercosis in a Rural Area of Northern Rwanda

    Frontiers in Veterinary Science, Vol. 8

2020

  1. A case of Echinococcus granulosus hepatic hydatid cyst together with pyogenic liver abscess in a Nepali patient

    Journal of Parasitic Diseases, Vol. 44, Núm. 2, pp. 472-475

  2. Candesartan cilexetil in vitro–in vivo correlation: Predictive dissolution as a development tool

    Pharmaceutics, Vol. 12, Núm. 7, pp. 1-21

  3. New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 18, pp. 1-30

2019

  1. A case report of human gastrodiscoidiasis in Nepal

    Parasitology International, Vol. 71, pp. 56-58

  2. Covalently crosslinked organophosphorous derivatives-chitosan hydrogel as a drug delivery system for oral administration of camptothecin

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 136, pp. 174-183

  3. Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

    Molecular Pharmaceutics, Vol. 16, Núm. 6, pp. 2418-2429

  4. Ion-pair approach coupled with nanoparticle formation to increase bioavailability of a low permeability charged drug

    International Journal of Pharmaceutics, Vol. 557, pp. 36-42

  5. Non-related contact lens coinfection with Acanthamoeba and Fusarium

    Asian Pacific Journal of Tropical Medicine, Vol. 12, Núm. 10, pp. 479-482

2018

  1. Closed-Loop Doluisio (Colon, Small Intestine) and Single-Pass Intestinal Perfusion (Colon, Jejunum) in Rat—Biophysical Model and Predictions Based on Caco-2

    Pharmaceutical Research, Vol. 35, Núm. 1

  2. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation

    European Journal of Pharmaceutical Sciences, Vol. 119, pp. 200-207

  4. Functional magnetic mesoporous silica microparticles capped with an azo-derivative: A promising colon drug delivery device

    Molecules, Vol. 23, Núm. 2

  5. Ionic Hydrogel Based on Chitosan Cross-Linked with 6-Phosphogluconic Trisodium Salt as a Drug Delivery System

    Biomacromolecules, Vol. 19, Núm. 4, pp. 1294-1304

  6. Long-circulating hyaluronan-based nanohydrogels as carriers of hydrophobic drugs

    Pharmaceutics, Vol. 10, Núm. 4